In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boston Scientific expecting 20%-plus sales growth despite near-term absence from stent market.

This article was originally published in The Gray Sheet

Executive Summary

BOSTON SCIENTIFIC PROJECTING 20%-PLUS REVENUE GROWTH IN 1998 despite the negative top-line impact likely to stem from the firm's absence from the $1 bil. U.S. coronary stent market. The company, which generated sales of nearly $1.9 bil. in 1997, hopes to enter the stent market by June with the NIR ON Ranger stent system; a premarket approval application was submitted on Jan. 28 ("The Gray Sheet" Feb. 2, In Brief).



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts